---
title: FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 06/2024 published - FCF Fox Corporate Finance GmbH
description: FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024”. The Monitor is a monthly published overview of venture capital trends in the ... Read more
---

[Research ](https://www.fcf.de/en/resources/research)

# [FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 06/2024 published - FCF Fox Corporate Finance GmbH](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-05-2024-published)

 Written by [FCF Healthcare & Life Sciences](https://www.fcf.de/en/resources/research/author/fcf-healthcare-life-sciences) | Jul 17, 2024 6:00:00 AM

FCF Fox Corporate Finance GmbH is delighted to publish the new “**FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024**”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

**As of the end of June 2024 we identify the following current VC trends in Europe:**

- Total Healthcare & Life Sciences funding reached EUR 4,110m.
- Biotech received 59% of the total investment volume (EUR 2,439m) with oncology being the leading indication (50%).
- In June, Bright Peak Therapeutics (Switzerland) secures the highest transaction volume with EUR 83m, followed by iOnctura (Switzerland) with EUR 80m and UroMems (France) with EUR 44m.
- European Innovation Council Fund (Belgium) is the most active investor (by deal volume), followed by M&G Investments (United Kingdom) and Patient Square Capital (United States).

To access the full report, please click [here](https://www.fcf.de/resources/research/download-request-fcf-healthcare-life-sciences-research-series-europe?hsLang=en).

[View full post](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-05-2024-published)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "FCF Healthcare & Life Sciences"
  },
  "dateModified" : "2025-11-11T15:43:33.348Z",
  "datePublished" : "2024-07-17T06:00:00Z",
  "headline" : "FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 06/2024 published",
  "image" : {
    "@type" : "ImageObject",
    "height" : 3563,
    "url" : "https://145785926.fs1.hubspotusercontent-eu1.net/hubfs/145785926/Website/Ressourcen/Healthcare_EU-Monitor_Shutterstock_2360267017_reduziert.jpeg",
    "width" : 9504
  },
  "mainEntityOfPage" : "https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-05-2024-published",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Research"
  }
}
```